Given that attempts to administer recombinant proteins have failed in this therapeutic context, systemic or intratumoral TRAIL gene transfer therapy has been identified as a potentially viable alternative approach to cancer treatment [13–15]. This evidence concerns the gene TNFSF10 and cancer.